TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1363660
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg o.d.)
Study: 28823927
Drug: Daily medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily medication reminders via SMS text messages
Study: 28823927
Drug: Medication monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication monitoring via a patient portal-based assessment
Study: 28823927
Drug: Both SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SMS text message reminders and portal-based medication monitoring
Study: 25624429
Drug: Orteronel 400
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orteronel 400 mg plus prednisone 5 mg twice daily
Study: 22033040
Drug: budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol pMDI 320/9 μg
Study: 22033040
Drug: budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol pMDI 160/9 μg
Study: 22383665
Drug: formoterol dry
Normalized name: aclidinium / formoterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol dry powder inhaler 9 μg
Study: 15212192
Drug: Fast-release orodispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-release orodispersible tramadol tablet (Zamadol Melt)
Study: 15212192
Drug: Conventional tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tramadol capsule
Study: 9700035
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with olive-allergen extracts (Stallergènes SA), 20 drops of 300 IR daily for 2 years
Study: 9700035
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with olive-allergen extracts (Stallergènes SA)
Study: 2691496
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic therapy for high-risk breast cancer
Study: 2691496
Drug: Primary (neoadjuvant)
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary (neoadjuvant) chemotherapy
Study: 30137340
Drug: 300mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg of micafungin twice weekly
Study: 30137340
Drug: 100mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg of micafungin once daily
Study: 30137340
Drug: 700mg once
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700mg once weekly (hypothetical regimen)
Study: 20094786
Drug: Conventional method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional method with administration of antispasmodics
Study: 1502960
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) with Haloperidol (30 mg/day)
Study: 6144974
Drug: Chemo-endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-endocrine therapy (CMFp + T)
Study: 6144974
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (p + T)
Study: 25262519
Drug: Flying Needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flying Needle and Chinese herbal medicine
Study: 20233180
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg as 30-min intravenous infusion without probenecid
Study: 20233180
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg as 30-min intravenous infusion with 3 g probenecid divided into five oral doses
Study: 19094670
Drug: 7 day
Normalized name: ZonaCort 7 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day steroid withdrawal group
Study: 19094670
Drug: 3 month
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 month steroid withdrawal group
Study: 16197815
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose IGF-1 (3 microg/kg of body weight)
Study: 16197815
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose IGF-1 (0.5 microg/kg of body weight)
Study: 12390211
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (lansoprazole, amoxicillin, metronidazole)
Study: 12390211
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus vitamin C (250 mg) and vitamin E (200 mg)
Study: 12390211
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (lansoprazole, amoxicillin, metronidazole) for metronidazole susceptible isolates
Study: 12390211
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus vitamin C and E for metronidazole susceptible isolates
Study: 10558313
Drug: Oral intubation
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intubation with the Trachlight
Study: 10558313
Drug: Nasal and
Normalized name: Nasal and Sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal and oral intubation
Study: 7747709
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) + Chemotherapy (CT)
Study: 7747709
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) + Chemotherapy (CT) + Protein-bound polysaccharide (PSK)
Study: 2117622
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose pro‐urokinase (9 million U)
Study: 2117622
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (4.5 million U pro‐urokinase and 0.2 million U urokinase)
Study: 2117622
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose pro‐urokinase
Study: 28501884
Drug: Methylprednisolone (32‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (32‐8 mg once daily for 20 days)
Study: 23645692
Drug: D-dimer levels
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer levels ≥ 221 ng/mL (upper quartile)
Study: 23645692
Drug: D-dimer levels
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer levels between 221 ng/mL and upper tertile
Study: 23645692
Drug: D-dimer levels
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer levels between lower tertile and 221 ng/mL
Study: 23645692
Drug: D-dimer levels
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer levels < 221 ng/mL (reference group)
Study: 17545090
Drug: Intubation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intubation at 1 min after rocuronium administration
Study: 17545090
Drug: Intubation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intubation at 2-4 min after rocuronium administration
Study: 17545090
Drug: Suppression of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppression of neuromuscular function at 1 min after rocuronium administration
Study: 11118390
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for wasting
Study: 9688002
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplements (320 mg twice daily)
Study: 10207294
Drug: Indobufen 200
Normalized name: indobufen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 200 mg/day and heparansulphate 200 mg/day
Study: 10207294
Drug: Indobufen 200
Normalized name: indobufen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 200 mg/day
Study: 6356903
Drug: Labetalol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol alone or in combination with furosemide
Study: 31532789
Drug: DNA-IIV3 (trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA-IIV3 (trivalent hemagglutinin DNA prime followed by trivalent inactivated influenza vaccine boost with a 3.5 month interval, administered intradermally)
Study: 31532789
Drug: IIV3-IIV3 (IIV3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV3-IIV3 (IIV3 prime followed by IIV3 boost with a 10 month interval, administered intramuscularly)
Study: 31532789
Drug: DNA/IIV3-IIV3 (concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA/IIV3-IIV3 (concurrent DNA and IIV3 prime followed by IIV3 boost with a 10 month interval)
Study: 31532789
Drug: IIV3 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV3 administered by ID route
Study: 31532789
Drug: IIV3 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV3 administered by IM route
Study: 31532789
Drug: DNA vaccine
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccine administered by Biojector
Study: 27073876
Drug: Serum 25(OH)D3
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D3 (per 10 nmol/L)
Study: 20645078
Drug: Methylphenidate (mean:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (mean: 14.7 mg; range: 10‐30 mg)
Study: 15819974
Drug: ABC/EFV/ddI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC/EFV/ddI plus HU (500 mg twice daily)
Study: 11990302
Drug: Native E.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native E. coli L-asparaginase
Study: 8444395
Drug: Single-dose ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ciprofloxacin 250 mg p.o.
Study: 8444395
Drug: Two-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day treatment with ciprofloxacin 250 mg bid
Study: 8444395
Drug: Three-day treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day treatment with ciprofloxacin 2 x 250 mg/day
Study: 2431013
Drug: Intralesional bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional bleomycin at 0.25 U/ml
Study: 2431013
Drug: Intralesional bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional bleomycin at 0.5 U/ml
Study: 2431013
Drug: Intralesional bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional bleomycin at 1 U/ml
Study: 30252913
Drug: Metformin DR
Normalized name: DR-01
DrugBank: DR-01 (DB18258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin DR 1200 mg
Study: 30252913
Drug: Metformin DR
Normalized name: DR-01
DrugBank: DR-01 (DB18258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin DR 1500 mg
Study: 30252913
Drug: Metformin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin IR 1000 mg
Study: 30252913
Drug: Metformin DR
Normalized name: DR-01
DrugBank: DR-01 (DB18258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin DR (normalized efficacy)
Study: 30252913
Drug: Metformin DR
Normalized name: DR-01
DrugBank: DR-01 (DB18258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin DR
Study: 26468213
Drug: Telemedicine (home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine (home treatment by video conferences)
Study: 20400409
Drug: Tipranavir (1250/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipranavir (1250/100 mg) + Ritonavir
Study: 20400409
Drug: Tipranavir (750/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipranavir (750/100 mg) + Ritonavir
Study: 20400409
Drug: Tipranavir (250/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipranavir (250/200 mg) + Ritonavir
Study: 10488481
Drug: suppressive hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: suppressive hormone administration
Study: 10488481
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of non-suppressive hormone therapy with low dose iodide (50-150 micrograms/day)
Study: 10488481
Drug: mere iodide
Normalized name: Echothiophate Iodide
Approvals — FDA: no, EMA: no, PMDA: no
Description: mere iodide in doses of 200 micrograms/day
Study: 8703875
Drug: Intraoperative mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative mitomycin C (0.2 mg/ml solution for 3 minutes)
Study: 1499364
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine (10-40 mg/d), enalapril (5-20 mg/d), and hydrochlorothiazide (12.5-25 mg/d) as necessary.
Study: 1499364
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebos to active treatment).
Study: 30304714
Drug: Proactive, high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive, high-dose IV iron (iron sucrose 400 mg/month unless ferritin > 700 μg/L and/or TSAT ≥40%)
Study: 30304714
Drug: Reactive, low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive, low-dose IV iron (iron sucrose administered if ferritin <200 μg/L or TSAT < 20%)
Study: 30304714
Drug: Proactive, high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive, high-dose IV iron
Study: 30304714
Drug: Reactive, low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive, low-dose IV iron
Study: 24090048
Drug: Sacha inchi
Normalized name: Abies sachalinensis var. sachalinensis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacha inchi oil (10 or 15 ml)
Study: 24090048
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (10 or 15 ml)
Study: 22751085
Drug: levodopa/benserazide, 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/benserazide, 100/25 mg with domperidone, 10 mg
Study: 22751085
Drug: levodopa/benserazide, 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/benserazide, 100/25 mg
Study: 17566120
Drug: Isosmotic macrogol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosmotic macrogol electrolyte solution (MC-ES)
Study: 15598680
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.67 mg/d)
Study: 12047731
Drug: Carbamazepine (600-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (600-800 mg on day 1 tapering to 200 mg)
Study: 12047731
Drug: Lorazepam (6-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (6-8 mg on day 1 tapering to 2 mg)
Study: 7639218
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) 120 mg
Study: 7639218
Drug: CBS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS plus amoxicillin (500 mg)
Study: 7639218
Drug: CBS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS plus metronidazole (400 mg)
Study: 7639218
Drug: CBS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS plus metronidazole and amoxicillin
Study: 7639218
Drug: CBS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS plus metronidazole and tetracycline (500 mg)
Study: 2172401
Drug: Interferon-alpha preparations
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha preparations (combined)
Study: 790554
Drug: Ketoprofen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (150 mg daily for 14 days)
Study: 790554
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg daily for 14 days)
Study: 30902750
Drug: liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 3.0 mg plus phentermine 15.0 mg
Study: 20537748
Drug: VAL 320
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VAL 320 mg/d
Study: 10475617
Drug: HIDAC (High
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIDAC (High Dose Cytarabine)
Study: 10475617
Drug: HIDAC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIDAC + M (High Dose Cytarabine plus Mitoxantrone)
Study: 1775609
Drug: Carbamazepine 200
Normalized name: carbamazepine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 200 mg or 400 mg
Study: 7011362
Drug: Soya-bean flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya-bean flour with 22 g saponins/kg
Study: 7011362
Drug: Soya-bean flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya-bean flour with 4 g saponins/kg
Study: 28600189
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg simvastatin
Study: 25516625
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg simvastatin plus 10 mg ezetimibe
Study: 18055183
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion (600mg/12h)
Study: 18055183
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (300mg intravenous loading dose + 900mg continuous infusion on Day 1, followed by 1200mg/daily from Day 2)
Study: 15649191
Drug: Brivudin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivudin (125 mg, once a day for 7 days)
Study: 15649191
Drug: Famciclovir (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir (250 mg, three times a day for 7 days)
Study: 12867222
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg, increased to losartan 50 mg/HCTZ 12.5 mg at week 6 and losartan 100 mg/HCTZ 25 mg at week 12
Study: 12867222
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg, increased to amlodipine 10 mg at week 6 and amlodipine 10 mg/HCTZ 25 mg at week 12
Study: 6612231
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic treatment with ampicillin 2 g X 4 + cloxacillin 1 g X 4 for 4 days
Study: 6612231
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without antibiotics
Study: 26968844
Drug: Sulfasalazine 3
Normalized name: sulfasalazine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine 3 g daily
Study: 25876342
Drug: Warm acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm acupuncture combined with auricular point sticking therapy
Study: 25876342
Drug: Estazolam tablets
Normalized name: Estazolam Tablets
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estazolam tablets (0.5 to 1 mg)
Study: 22595139
Drug: Subcutaneous supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous supplementation of a trace mineral supplement containing Zn, Mn, Se, and Cu at 230 days of gestation and 260 days of gestation
Study: 11900939
Drug: Collagen/elastin dermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen/elastin dermal substitute in combination with an autograft
Study: 10511608
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with omeprazole (20 mg twice daily), amoxicillin (1000 mg), and clarithromycin (500 mg) for 14 days
Study: 10511608
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment and H. pylori-negative patients
Study: 10511608
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment and H. pylori-positive patients
Study: 7381554
Drug: CT assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT assessments before initiating radio-chemotherapy and at the completion of each cycle
Study: 30178187
Drug: Small tidal
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small tidal volume (STV) ventilation (3-5 mL/kg)
Study: 30178187
Drug: Large tidal
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large tidal volume (LTV) ventilation (6-8 mL/kg)
Study: 27789115
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg orally
Study: 27789115
Drug: Meclizine 25
Normalized name: meclizine 25 MG
DrugBank: Meclizine (DB00737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclizine 25 mg orally
Study: 25393080
Drug: Melatonin/hypothermia group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin/hypothermia group (N=15; received hypothermia and five daily enteral doses of melatonin 10 mg kg(‐1))
Study: 24412265
Drug: Foot-drop stimulator
Normalized name: Fungi-Nail Toe and Foot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot-drop stimulator (FDS; Bioness L300) used for ambulation over 42 weeks after 8 physical therapy sessions
Study: 17270006
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg (single dose)
Study: 17270006
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg and esomeprazole 40 mg (single doses)
Study: 17270006
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg (5 days' dosing)
Study: 17270006
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg vs. rabeprazole 10 mg (5 days' dosing)
Study: 15650984
Drug: diclofenac/paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac/paracetamol